DeVore R F, Corbett A H, Osheroff N
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146.
Cancer Res. 1992 Apr 15;52(8):2156-61.
The effects of serine phosphorylation on the DNA cleavage/religation equilibrium of topoisomerase II and the sensitivity of the enzyme to antineoplastic drugs were characterized. Both casein kinase II and protein kinase C were used for these studies. Each kinase incorporated a maximum of approximately 1.4 phosphate molecules per homodimer of topoisomerase II. When the enzyme was incubated with both kinases simultaneously, phosphate incorporation increased to approximately 2.6 molecules/homodimer. In the absence of antineoplastic drugs, phosphorylation had only a slight effect on the DNA cleavage/religation equilibrium of topoisomerase II. However, in the presence of etoposide or 4'-(9-acridinylamino)methane-sulfon-m-anisidide, phosphorylation attenuated the ability of drugs to stabilize enzyme-DNA cleavage complexes. Levels of drug-induced DNA cleavage products decreased approximately 33% following phosphorylation of topoisomerase II by casein kinase II, approximately 17% following modification by protein kinase C, and approximately 50% following simultaneous phosphorylation of the enzyme by both kinases. This latter 50% reduction in DNA cleavage products correlated with an approximately 2-fold increase in the apparent first order rate constant for DNA religation mediated by simultaneously modified topoisomerase II. These results strongly suggest that the sensitivity of topoisomerase II toward antineoplastic drugs can be modulated by altering the phosphorylation state of the enzyme.
研究了丝氨酸磷酸化对拓扑异构酶II的DNA切割/连接平衡以及该酶对抗肿瘤药物敏感性的影响。酪蛋白激酶II和蛋白激酶C均用于这些研究。每种激酶在拓扑异构酶II的每个同二聚体上最多掺入约1.4个磷酸分子。当该酶与两种激酶同时孵育时,磷酸掺入量增加至约2.6个分子/同二聚体。在没有抗肿瘤药物的情况下,磷酸化对拓扑异构酶II的DNA切割/连接平衡只有轻微影响。然而,在存在依托泊苷或4'-(9-吖啶基氨基)甲磺基间茴香胺的情况下,磷酸化减弱了药物稳定酶-DNA切割复合物的能力。酪蛋白激酶II使拓扑异构酶II磷酸化后,药物诱导的DNA切割产物水平降低约33%,蛋白激酶C修饰后降低约17%,两种激酶同时使该酶磷酸化后降低约50%。DNA切割产物的后一种50%的减少与同时修饰的拓扑异构酶II介导的DNA连接的表观一级速率常数增加约2倍相关。这些结果强烈表明,拓扑异构酶II对抗肿瘤药物的敏感性可通过改变该酶的磷酸化状态来调节。